The mean prevalence of seizures in different types of glioma is around 60%, ranging from 34% in glioblastoma, isocitrate dehydrogenase-wildtype, up to 94% in dysembryoblastic neuro-epithelial tumors, whereas 23% of patients with BMs develop seizures.48,49 Expanding our knowledge on seizure outcomes in BMs has become clinically more relevant, as the number and survival of patients with BMs is increasing, resulting in a higher risk of long-term burden of epilepsy in this patient group. This evidence concerns the gene IDH3A and central nervous system cancer.